CT-02 / Captor Therap - LARVOL DELTA

Captor Therapeutics Announces Three-Year Strategic Objectives (GlobeNewswire) - "Initiate the clinical development by Captor of its advanced projects CT-01 (Hepatocellular carcinoma) and CT-03 (haematological malignancies) in 2023 and 2024 respectively, with clinical data readouts in 2024 and 2025. Advance Captor's early pipeline assets in inflammation (CT-02, CT-05) to in-vivo proof of efficacy in 2023 as a prelude to collaborative development."

Clinical data • New trial • Preclinical • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Immunology • Leukemia • Liver Cancer • Oncology • Solid Tumor